Home › Funds › Whitefort Capital Management, LP › ABUS
Whitefort Capital Management, LP position in ABUS
ARBUTUS BIOPHARMA CORP · Health Care
Whitefort Capital Management, LP reported holding 15,794,261 shares of ABUS (ARBUTUS BIOPHARMA CORP) in its Q2 2026 13F filing — a position valued at US$75.8M, representing 19.36% of its reported portfolio and ranking #1 among its reported holdings. Whitefort Capital Management, LP has disclosed ABUS holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Whitefort Capital Management, LP's ABUS position evolved
Whitefort Capital Management, LP first disclosed a stake in ABUS in Q3 2023 at 11,895,477 shares (US$24.1M). The position peaked in Q2 2026 at 15,794,261 shares, worth US$75.8M. Across 12 filings, Whitefort Capital Management, LP increased the stake 4 time(s), trimmed it 1 time(s) and left it unchanged 6 time(s). The most recent filing (Q2 2026) shows 15,794,261 shares valued at US$75.8M — an increase of 863,376 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 11.90M | $24.15M | New |
| Q4 2023 | 13.20M | $32.99M | Add |
| Q1 2024 | 12.86M | $33.18M | Reduce |
| Q2 2024 | 12.87M | $39.76M | Hold |
| Q3 2024 | 12.87M | $49.54M | Hold |
| Q4 2024 | 13.24M | $43.30M | Add |
| Q1 2025 | 13.31M | $46.44M | Hold |
| Q2 2025 | 13.34M | $41.23M | Hold |
| Q3 2025 | 13.34M | $60.58M | Hold |
| Q4 2025 | 13.34M | $64.18M | Hold |
| Q1 2026 | 14.93M | $67.19M | Add |
| Q2 2026 | 15.79M | $75.81M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ABUS and 13F data
ABUS (ARBUTUS BIOPHARMA CORP) is a Health Care company. 43 other funds we track also report a position in ABUS — the largest reported positions include Two Seas Capital LP (US$38.9M), BlackBarn Capital Partners LP (US$12.0M), Deltroit Asset Management (UK) LLP (US$5.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ABUS
- Two Seas Capital LP 8.14M sh · $38.93M · Q3 2026
- BlackBarn Capital Partners LP 2.50M sh · $12.00M · Q2 2026
- Deltroit Asset Management (UK) LLP 1.20M sh · $5.76M · Q2 2026
- Western Standard LLC 542.79K sh · $2.61M · Q2 2026
- Rangeley Capital, LLC 500.00K sh · $2.40M · Q2 2026
More on Whitefort Capital Management, LP
FAQ
How long has Whitefort Capital Management, LP held ABUS?
Whitefort Capital Management, LP has disclosed ABUS holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is Whitefort Capital Management, LP's current position in ABUS?
As of Q2 2026, Whitefort Capital Management, LP holds 15.79M shares of ABUS (ARBUTUS BIOPHARMA CORP), valued at $75.81M, representing 19.36% of its reported portfolio and ranking #1.
Has Whitefort Capital Management, LP been buying or selling ABUS?
In the latest 13F filing (Q2 2026), Whitefort Capital Management, LP increased its position in ABUS. The position peaked in Q2 2026 at 15.79M shares.
Which other funds hold ABUS?
Other major institutional holders of ABUS include Two Seas Capital LP, BlackBarn Capital Partners LP, Deltroit Asset Management (UK) LLP, among 43 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.